Pharma & Biotech Insights, Interviews & Features
Today's issue
Refine Search
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 7 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 31 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Biosimilars
It was no fluke when Celltrion Healthcare became the first drug developer to win approval for a biosimilar monoclonal antibody (mAb) from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) with its copy of Remicade (infliximab). 13 April 2018
Pharmaceutical
When pharma bosses talk about innovation, they are referring both to the research and development (R&D) that goes into discovering and bringing new medicines to market that offer valuable benefits for patients, and to the money that goes into paying for that work. 11 April 2018
Pharmaceutical
If it were ever doubted that cannabis-based therapies would one day occupy space in certain specialists’ armamentaria, that time has now certainly passed. 11 April 2018
Biosimilars
Though the cost of developing niche complex drugs and biosimilars is substantially high, the potential opportunity has got Indian drug majors in a frenzy, reports The Pharma Letter’s India correspondent. 10 April 2018
Generics
The Russian Federal Anti-Monopoly Service (FAS) suspects R-Pharm, one of the country’s suppliers of drugs for state needs, is in illegal collusion with the country’s Ministry of Health, which may allow the company to receive large-scale contracts with the state, reports The Pharma Letter’s local correspondent. 9 April 2018
Pharmaceutical
Russian millionaire Viktor Kharitonin has consolidated the 100% stake in Pharmstandard, one of Russia’s largest drugmakers and one of the largest suppliers of drugs for state purchases, according to the company, reports The Pharma Letter’s local correspondent. 9 April 2018
Pharmaceutical
China in June 2017 became a member of the e International Council for Harmonization (ICH), showing the world how determined it is to be a global player. In January, the China Food and Drug Administration (CFDA) announced it will gradually adopt ICH E2A, the guideline for clinical safety data management, by July 1, 2022, reports Wang Fangqing, The Pharma Letter’s local correspondent. 9 April 2018
Pharmaceutical
Matthew Majewski, vice president at Charles River Associates' Life Sciences Practice, considers the need for new pricing models in an Expert View column. 6 April 2018
Biotechnology
Many high-profile startsups prefer crashing in crowded mega Chinese cities. For example, Zai Lab is located in Shanghai, and BeiGene chose to stay in Beijing, comments The Pharma Letter’s China correspondent Wang Fangqing. 5 April 2018
Pharmaceutical
For many patients, brands like Nurofen (ibuprofen) and Claritin (loratadine) are household names. They retain a prominent place on supermarket shelves and sell extremely well with an established consumer base despite having been off-patent for many years, with their cheaper generic counterparts invariably displayed alongside them. 5 April 2018
Biotechnology
Nordic Nanovector saw its share plunge 9.66% to 4.21 euros as markets opened this mornings, after the Norway-based biotech firm revealed that its chief executive, Luigi Costa, will step down from the post by mutual agreement with the board of directors. 5 April 2018
Biosimilars
Our latest Special Report is a review of key factors impeding progress of US biosimilar adoption written by Helen Ji, an associate at Schiff Hardin LLP, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines. 4 April 2018
Pharmaceutical
At first glance, the global pharmaceutical industry, often regarded as slow-moving, conservative and resistant to change, appears infertile ground for an innovation like blockchain to take hold. 3 April 2018
Biotechnology
US gene therapy developer Abeona Therapeutics has lured one of the most experienced names in rare diseases to become its new chief executive. 3 April 2018
Pharmaceutical
Dermavant has expanded not just its pipeline, but also its executive team, the dermatology specialist announced on Monday. 3 April 2018
Biotechnology
Celgene Corp on Monday announced that Scott Smith, president and chief operating officer (COO), is leaving the company effective immediately. 3 April 2018
Pharmaceutical
Menarini, one of Italy’s largest pharma companies and still headed by the founding Aleotti family, has decided to entrust the chairmanship of the company to an external manager coming from a large multinational, Dr Eric Cornut. 29 March 2018
Pharmaceutical
Business, technical, and financial incentives are driving the rapid adoption of cloud-based, commercially available solutions in pharmaceutical research and operations, writes Frank Lin, consultant at Halloran Consulting Group, in an Expert View piece. 27 March 2018
Pharmaceutical
Survivors of drug resistant tuberculosis TB), health organizations and the TB community in India are urging the government to institute a compulsory licence on two new-generation drugs: bedaquiline and delamanid. 27 March 2018
Pharmaceutical
After 19 years with the US healthcare giant Johnson & Johnson (NYSE: JNJ), Dominic Caruso, executive vice president, chief financial officer, has elected to retire in September 2018. 22 March 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze